News

Net profit of Fredun Pharmaceuticals rose 93.94% to Rs 13.13 crore in the quarter ended June 2026 as against Rs 6.77 crore during the previous quarter ended June 2025. Sales rose 90.75% to Rs 227.76 crore in the quarter ended June 2026 as against Rs 119.40 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales227.76119.40 91 OPM %14.3714.23 - PBDT24.1210.46 131 PBT20.559.04 127 NP13.136.77 94 Powered by Capital Market - Live News

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Fredun Pharmaceuticals announced that the 39th Annual General Meeting(AGM) of the company will be held on 30 June 2026.

Net profit of Fredun Pharmaceuticals rose 79.67% to Rs 10.78 crore in the quarter ended March 2026 as against Rs 6.00 crore during the previous quarter ended March 2025. Sales rose 27.18% to Rs 210.41 crore in the quarter ended March 2026 as against Rs 165.44 crore during the previous quarter ended March 2025.For the full year,net profit rose 65.25% to Rs 32.62 crore in the year ended March 2026 as against Rs 19.74 crore during the previous year ended March 2025. Sales rose 40.21% to Rs 633.33 crore in the year ended March 2026 as against Rs 451.71 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales210.41165.44 27 633.33451.71 40 OPM %13.7310.43 -13.9212.16 - PBDT14.409.10 58 55.2432.53 70 PBT11.257.26 55 47.0027.49 71 NP10.786.00 80 32.6219.74 65 Powered by Capital Market - Live News

The board of Fredun Pharmaceuticals at its meeting held on May 25, 2026, wherein the audited financial results for Q4 and FY26 were approved, has recommended the issuance of bonus shares in the ratio of 2:1, i.e. 2 fully paid-up equity shares of Rs 10 each for every 1 existing equity share of Rs 10 each, to eligible shareholders and warrant holders as on the record date, subject to shareholder approval.